ASF Guest Symposium
The Alport Syndrome Foundation is pleased to sponsor a Guest Symposium at this year’s American Society for Matrix Biology (ASMB) Biennial Meeting, which will be held October 14-17 at Red Rock Casino Resort Spa near Las Vegas. The ASF Guest Symposium will be held Sunday morning October 14 from 10 am to noon. There will be three invited Speakers and two slots for short talks chosen from submitted abstracts. ASF will provide $400 travel awards for the two junior faculty and/or trainees who will be chosen to present their abstract orally during the Guest Symposium. Please see the ASMB website for details regarding program, registration, housing, and abstract submission. The deadline for submission is June 25. This will be an excellent opportunity to meet other Alport syndrome researchers and learn about the latest discoveries in extracellular matrix biology.
October 14, 2018
Moderator: Jeffrey Miner, Washington University School of Medicine, St. Louis
10:00 Gautam Jay Bhave, Vanderbilt University Medical Center, Nashville
Biochemical Mechanisms of Collagen IV Assembly
10:30 Rachel Lennon, University of Manchester, Manchester, UK
Proteomics of the Glomerular Basement Membrane in Alport Syndrome
11:00 Keith Hruska, Washington University School of Medicine, St. Louis
Targeting the Activin Receptor to Slow Progression of Alport Syndrome
11:30 Short talk 1
11:45 Short talk 2
March is #AlportAwareness Month
Help us spread education and awareness about Alport syndrome all month! Be sure to follow us on social media and share our posts on your respective channels using #AlportAwareness. Learn other ways to get involved.
Arizona 5K for Healthy Kidneys
Our 11th Annual Arizona 5K for Healthy Kidneys will take place on April 29, 2018 at Kiwanis Park in Tempe, AZ. Register today to join and/or fundraise.
Alport syndrome Research Studies
Recruiting for the ATHENA observational study conducted by Regulus Therapeutics is now closed. This study sought to learn more about the natural history of Alport syndrome. No medications were administered as part of the study.
The CARDINAL study is an interventional Phase 2/3 study conducted by Reata Pharmaceuticals to test the effectiveness of the drug bardoxolone methyl in treating chronic kidney disease caused by Alport syndrome. Initial CARDINAL Phase 2 data is available via Webex.
Phase 3 of CARDINAL is currently recruiting in the US. Additional international sites will be announced once they are ready for screening. Phase 3 is a double-blind placebo-controlled study.
The HERA study is an interventional Phase 2 clinical study conducted by Regulus Therapeutics. The study will evaluate the safety and effectiveness of an investigational drug called RG-012. The study is expected to begin recruiting in fall 2017.
Ask the Experts Webinar Series
ASF hosts a monthly webinar series where experts address topics of interest to the Alport syndrome community. Recordings of past webinars can be found on our website and the ASF YouTube channel.
Free Continuing Medical Education Course
ASF is sponsoring a one-hour free continuing medical education (CME) course for medical professionals. The course focuses on the fundamentals of Alport syndrome, including diagnosis, treatment, and management of the disease.
Alport syndrome Renal Nutrition Guide
ASF is proud to share our first-ever Renal Nutrition Guide to help patients make kidney-friendly food choices.
ASTOR Patient Registry
Participating in the patient registry allows patients, family members, and physicians to be informed of new clinical studies and trials. Join today!
Support ASF While You Shop
Support ASF while you shop online at Amazon, Best Buy, Nike, and thousands of other stores, including the ASF Store. Learn how!
Register today to receive the ASF newsletter each month.